<DOC>
	<DOC>NCT02468089</DOC>
	<brief_summary>A Minimum of 150 consecutive patients of decompensated cirrhosis of any etiology, presenting to the Institute of Liver and Biliary Sciences hospital with a diagnosis of difficult to treat SBP will be included and randomized into two treatment groups. Group A - Carbepenem+albumin Group B - Carbepenem+albumin+GMCSF.</brief_summary>
	<brief_title>To Compare the Efficacy of Carbepenem Versus Carbepenem Plus GM-CSF in Difficult To Treat Spontaneous Bacterial Peritonitis</brief_title>
	<detailed_description />
	<mesh_term>Peritonitis</mesh_term>
	<criteria>1. Age more than 18 years 2. Patients of decompensated liver cirrhosis who present with Spontaneous bacterial peritonitis (Presence of more than 250 neutrophils per cc of ascetic fluid, in the absence of a surgical abdomen, in the presence of decompensated cirrhosis and portal hypertension) that is not responding to initial therapy DTTSBP: Hospital acquired New onset SBP (Spontaneous bacterial peritonitis) after 48 h of hospitalization. Recurrent SBP One or more prior episode(s) of SBP in year. Antibiotic resistant Resistance to 3rd Gen Cephalosporin in last 3 m. Antibiotic nonresponse Nonresponse to 3rd Gen Cephalosporin, sepsis on 3rd Gen Cephalosporin. 1. &lt; 18 years. 2. Advanced HCC (HepatoCellular Carcinoma) 3. Post liver transplant 4. HIV + ve, Immunosuppressive therapy 5. Pregnancy 6. Domiciliary treatment 7. No consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>